OKYO Pharma Limited (OKYO.L) Research

OKYO Pharma Limited, a biopharmaceutical entity operating at the preclinical stage, focuses on creating treatments for individuals experiencing inflammatory conditions of the eye and chronic ocular pain. Established in 2007 and headquartered in London, UK, the company's primary investigational drug is OK-101, aimed at addressing dry eye syndrome. Additionally, the firm is advancing OK-201, a preclinical analogue developed from bovine adrenal medulla, designed to alleviate neuropathic ocular pain.

Market snapshot

Symbol
OKYO.L
Price
$1.40
Day change
-24.32%
Market cap
$61.0M
P/E ratio
-12.90x
52-week range
0.0-8.5
Sector
Healthcare
Industry
Biotechnology

Peer companies

  • BiVictriX Therapeutics Plc (BVX.L)
  • C4X Discovery Holdings plc (C4XD.L)
  • Destiny Pharma plc (DEST.L)
  • Midatech Pharma plc (MTPH.L)
  • NetScientific plc (NSCI.L)
  • Oxford Cannabinoid Technologies Holdings Plc (OCTP.L)
  • ReNeuron Group plc (RENE.L)
  • Synairgen plc (SNG.L)

Open OKYO Pharma Limited (OKYO.L) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.